We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Approaches to Alzheimer's Disease

By Biotechdaily staff writers
Posted on 11 Jul 2005
A study has suggested radical new approaches to the diagnosis and treatment of Alzheimer's disease.

The investigators question the current theory that the dementia in Alzheimer's is caused by plaque deposits in the brain. More...
They argue that, instead, the disease may be caused by a fundamental defect in the brain's ability to configure the newly synthesized proteins that are necessary for memory. They offer evidence that the presence of beta-amyloid, the primary component of the plaque deposits, is only a marker of the dementia, rather than the cause. The study, from the laboratory of Jordan L. Holtzman at the University of Minnesota (Minneapolis, USA), was published in the June 24, 2005, issue of Biochemical Biophysical Research Communications.

The investigators outline several flaws in current approaches that link the disease to the toxicity of the beta-amyloid. They note that longitudinal studies of elderly subjects have shown that up to 40% of those with plaque deposits were not demented at the time of death. Similarly, despite the fact that beta-amyloid is produced in everyone, the deposits are only seen in the elderly. This suggests that the beta-amyloid is bound to carrier proteins, which keep it in solution. The study presents data indicting that Alzheimer's may result from a fundamental failure of the nerve cells to produce these carrier proteins.

Determining the levels of the carrier proteins in the cerebrospinal fluid may be a useful test to diagnose and monitor the disease, according to the researchers. Also, new agents should be developed that enhance the ability of cells to produce functional proteins, such as methoxychlor, shown effective in animal studies. In the meantime, drugs that either block the synthesis of the beta-amyloid or dissolve the plaque have been uniformly unsuccessful in moderating the disease.




Related Links:
University of Minnesota

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.